ACN_7.14_Full Issue digital | Page 8

Latest & Greatest

Could an AI Algorithm Diagnose DVT More Efficiently ?

Researchers from the University of Oxford and the University of Sheffield have teamed up with U . K . startup ThinkSono to develop a machine learning artificial intelligence ( AI ) algorithm that could help diagnose deep vein thrombosis ( DVT ) faster and more efficiently than traditional diagnostic scans .
The technology , called AutoDVT , may “ enable non-radiology staff such as nurses or junior doctors to perform DVT scans at the point of care , which can heavily shorten the DVT clinical pathway and reduce waiting times ,” particularly in remote rural areas and at shortstaffed hospitals , said Fouad Al Noor , CEO and cofounder of ThinkSono .
Preliminary results using AutoDVT coupled with a handheld ultrasound machine were promising , said Nicola Curry , MD , a researcher at University of Oxford ’ s Radcliffe Department of Medicine and clinician at Oxford University Hospitals NHS Foundation Trust .
Source : Forbes , September 21 , 2021 .
IMBRUVICA ® ( ibrutinib ) IMBRUVICA ® ( ibrutinib )
Table 5 : Adverse Reactions Reported in ≥ 10 % of Patients in the
IMBRUVICA Treated Arm in Patients with CLL / SLL in RESONATE-2
IMBRUVICA ( N = 135 )
Chlorambucil ( N = 132 )
Body System Adverse Reaction
All Grades (%)
Grade 3 or Higher (%)
All Grades (%)
Grade 3 or Higher (%)
Gastrointestinal disorders Diarrhea
42
4
17
0
Nausea
22
1
39
1
Constipation
16
1
16
0
Stomatitis *
14
1
4
1
Vomiting
13
0
20
1
Abdominal pain
13
3
11
1
Dyspepsia
11
0
2
0
Musculoskeletal and connective tissue disorders
Musculoskeletal pain *
36
4
20
0
Arthralgia
16
1
7
1
Muscle spasms
11
0
5
0
General disorders and administration site conditions
Fatigue
30
1
38
5
Peripheral edema
19
1
9
0
Pyrexia
17
0
14
2
Respiratory , thoracic and mediastinal disorders
Cough
22
0
15
0
Dyspnea
10
1
10
0
Skin and subcutaneous tissue disorders
Rash *
21
4
12
2
Bruising *
19
0
7
0
Eye disorders Dry eye
17
0
5
0
Lacrimation increased
13
0
6
0
Vision blurred
13
0
8
0
Visual acuity reduced
11
0
2
0
Infections and infestations Upper respiratory tract
17
2
17
2
infection
Skin infection *
15
2
3
1
Pneumonia *
14
8
7
4
Urinary tract infections
10
1
8
1
Vascular disorders Hypertension *
14
4
1
0
Nervous system disorders Headache
12
1
10
2
Dizziness
11
0
12
1
Investigations Weight decreased
10
0
12
0
Subjects with multiple events for a given ADR term are counted once only
for each ADR term .
The body system and individual ADR terms are sorted in descending frequency
order in the IMBRUVICA arm .
* Includes multiple ADR terms
Table 6 : Treatment-Emergent Hematologic Laboratory Abnormalities in
Patients with CLL / SLL in RESONATE-2
IMBRUVICA ( N = 135 )
Chlorambucil ( N = 132 )
All Grades
Grade 3 or 4
All Grades
Grade 3 or 4
(%)
(%)
(%)
(%)
Neutrophils Decreased
55
28
67
31
Platelets Decreased
47
7
58
14
Hemoglobin Decreased
36
0
39
2
Treatment-emergent Grade 4 thrombocytopenia ( 1 % in the IMBRUVICA arm
vs 3 % in the chlorambucil arm ) and neutropenia ( 11 % in the IMBRUVICA arm
vs 12 % in the chlorambucil arm ) occurred in patients .
HELIOS : Adverse reactions described below in Table 7 reflect exposure to IMBRUVICA + BR with a median duration of 14.7 months and exposure to placebo + BR with a median of 12.8 months in HELIOS in patients with previously treated CLL / SLL .
Table 7 : Adverse Reactions Reported in at Least 10 % of Patients and at Least 2 % Greater in the IMBRUVICA Arm in Patients with CLL / SLL in HELIOS
IMBRUVICA + BR Placebo + BR ( N = 287 )
( N = 287 )
All Grades (%)
Grade 3 or Higher (%)
All Grades (%)
Grade 3 or Higher (%)
Body System Adverse Reaction
Blood and lymphatic system
disorders
Neutropenia *
66
61
60
56 †
Thrombocytopenia *
34
16
26
16
Gastrointestinal disorders
Diarrhea
36
2
23
1
Abdominal pain
12
1
8
< 1
Skin and subcutaneous tissue
disorders
Rash *
32
4
25
1
Bruising *
20
< 1
8
< 1
Musculoskeletal and
connective tissue disorders
Musculoskeletal pain *
29
2
20
0
Muscle spasms
12
< 1
5
0
General disorders and
administration site conditions
Pyrexia
25
4
22
2
Vascular disorders
Hemorrhage *
19
2 †
9
1
Hypertension *
11
5
5
2
Infections and infestations Bronchitis
13
2
10
3
Skin infection *
10
3
6
2
Metabolism and nutrition disorders
Hyperuricemia
10
2
6
0
The body system and individual ADR terms are sorted in descending frequency
order in the IMBRUVICA arm .
* Includes multiple ADR terms
< 1 used for frequency above 0 and below 0.5 %
† Includes 2 events of hemorrhage with fatal outcome in the IMBRUVICA arm
and 1 event of neutropenia with a fatal outcome in the placebo + BR arm .
Atrial fibrillation of any grade occurred in 7 % of patients treated with
IMBRUVICA + BR and 2 % of patients treated with placebo + BR . The frequency
of Grade 3 and 4 atrial fibrillation was 3 % in patients treated with IMBRUVICA + BR
and 1 % in patients treated with placebo + BR .
iLLUMINATE : Adverse reactions described below in Table 8 reflect exposure
to IMBRUVICA + obinutuzumab with a median duration of 29.3 months and
exposure to chlorambucil + obinutuzumab with a median of 5.1 months in
iLLUMINATE in patients with previously untreated CLL / SLL .
Table 8 : Adverse Reactions Reported in at Least 10 % of Patients in the
IMBRUVICA Arm in Patients with CLL / SLL in iLLUMINATE
IMBRUVICA + Obinutuzumab ( N = 113 )
All Grades (%)
Grade 3 or Higher (%)
Chlorambucil + Obinutuzumab ( N = 115 )
All Grades (%)
Grade 3 or Higher (%)
Body System Adverse Reaction
Blood and lymphatic system
disorders
Neutropenia *
48
39
64
48
Thrombocytopenia *
36
19
28
11
Anemia
17
4
25
8
Skin and subcutaneous tissue
disorders
Rash *
36
3
11
0
Bruising *
32
3
3
0